Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807714 | 1.00 | NOTUM (0.54) | NOTUMF2F11PRSS1PRSS2 | |
| SCHEMBL29528817 | 0.95 | NOTUM (0.49) | NOTUMF2F11PRSS1PRSS2 | |
| SCHEMBL22498135 | 0.95 | NOTUM (0.49) | NOTUMF2F11PRSS1PRSS2 | |
| SCHEMBL16156661 | 0.88 | HIF1A (0.42) | NOTUMKDM4EALDH1A1DGAT1CA1 | |
| SCHEMBL14995907 | 0.86 | DGAT1 (0.39) | NOTUMKDM4EALDH1A1DGAT1CA1 | |
| SCHEMBL30963943 | 0.86 | NOTUM (0.41) | NOTUMF2F11PRSS1PRSS2 | |
| SCHEMBL2824607 | 0.86 | NOTUM (0.41) | NOTUMF2F11PRSS1PRSS2 | |
| SCHEMBL1814092 | 0.85 | KDM4E (0.44) | KDM4EALDH1A1DGAT1CA1CA2 | |
| SCHEMBL16244750 | 0.85 | HIF1A (0.38) | NOTUMKDM4EALDH1A1DGAT1CA1 | |
| SCHEMBL21695896 | 0.84 | NOTUM (0.48) | NOTUMCFTRCES2KDM4ECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2021203023-A1 | INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2640723-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013079223-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORϒ, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2013-06-06 | — | — | WO | disclosed |
| WO-2012139775-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2012068450-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | NOTUM 3490/4885F2 1041/4885F11 1531/4885 |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | NOTUM 2579/4885F2 4291/4885F11 4250/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | NOTUM 3365/4885F2 1171/4885F11 2080/4885 |
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | JAK2, JAK1, JAK3 | NOTUM 3502/4885F2 1076/4885F11 944/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | NOTUM 3948/4885F2 1008/4885F11 923/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | NOTUM 3574/4885F2 448/4885F11 76/4885 |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | NOTUM 3502/4885F2 1076/4885F11 944/4885 |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | NOTUM 3630/4885F2 4042/4885F11 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.